Overview

Safety and Efficacy of Fingolimod in MS Patients in China

Status:
Withdrawn
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride